Welcome to our dedicated page for Nanobiotix S.A. SEC filings (Ticker: NBTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nanobiotix S.A. filings document foreign private issuer reporting for a late-stage clinical biotechnology company developing nanoparticle-based therapeutic platforms. Recent Form 6-K reports furnish press-release exhibits covering JNJ-1900 (NBTXR3) clinical and regulatory disclosures, Nanoprimer preclinical data, operating and financial updates, and responses to corporate-status speculation.
The filing record also documents capital-structure and governance information, including share capital, theoretical and exercisable voting rights reported under French market rules, material agreements tied to development and commercialization collaborations, and foreign private issuer status on Form 20-F for its Euronext Paris and Nasdaq-listed securities.
NanoBiotix S.A. filed a current report stating that a corporate press release has been issued and is included as Exhibit 99.1 and incorporated by reference into the report. The filing is executed on the company’s behalf by Bart Van Rhijn, the Chief Financial Officer.
Nanobiotix S.A. reported interim results showing Total Revenue of €24.9 million for the six months ended June 30, 2025, driven primarily by a one‑off €21.2 million cumulative catch‑up from a contract modification with Janssen that increased the constrained transaction price. The company recorded a net loss of €5.4 million for the period and held €28.8 million of cash and equivalents as of June 30, 2025. Management estimates current resources finance operations into mid‑2026 and states additional liquidity of €8–10 million will be required over the next 12 months, creating a material uncertainty about going concern. The March 17, 2025 amendment shifts almost full financial responsibility for the NANORAY‑312 Phase 3 trial to Janssen and revises certain milestone amounts, adjusting total deal value to about $2.6 billion with royalties in the low‑teens to low‑20s percentages.